The real-world outcomes of multiple myeloma patients treated with daratumumab.
Most patients cannot be included in randomized clinical trials. We report real-world outcomes of all Danish patients with multiple myeloma (MM) treated with daratumumab-based regimens until 1 January 2019.<h4>Methods</h4>Information of 635 patients treated with daratumumab was collected...
Main Authors: | Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen, Eigil Kjeldsen, Katrine Fladeland Iversen, Elena Manuela Teodorescu, Marveh Dokhi, Eva Kurt, Casper Strandholdt, Mette Klarskov Andersen, Annette Juul Vangsted |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0258487 |
Similar Items
-
The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies
by: Agoston Gyula Szabo, et al.
Published: (2023-11-01) -
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
by: Katrine Fladeland Iversen, et al.
Published: (2022-08-01) -
Catheter‐directed thrombolysis for massive deep vein thrombosis in an adolescent with severe antithrombin deficiency
by: Søren Thorgaard Bønløkke, et al.
Published: (2022-04-01) -
Primique: automatic design of specific PCR primers for each sequence in a family
by: Lange Mette, et al.
Published: (2007-10-01) -
The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
by: Agoston Gyula Szabo, et al.
Published: (2019-08-01)